About the Cover
T cells and NK cells are important components of antitumor responses against many cancers. Unlike some other interleukins, IL15 will stimulate and promote proliferation of these immune cells, but not regulatory T cells. A superagonist called ALT-803, based on an IL15 variant complexed to a dimeric IL15 receptor α-Fc fusion protein, was found to be a powerful antitumor agent in multiple models, as described in the Research Article by Rhode and colleagues that begins on p. 49 of this issue of Cancer Immunology Research. Original micrograph (right) shows CD8+ T cells binding and internalizing ALT-803. Photo credit: Samantha Suriano of the Mark Rubinstein laboratory at the Medical University of South Carolina and used with permission. Artwork: Lewis Long.